Overactive Bladder News and Research

RSS

Overactive bladder (OAB) is a urological condition defined by a set of symptoms: "urgency, with or without urge incontinence, usually with frequency and nocturia."

Nerve growth factor may be dynamic marker of OAB pathophysiology

Urine levels of nerve growth factor fluctuate in line with changes in bladder pathophysiology, a 5-year study of people with overactive bladder has found.

10 Mar 2014

Antares Pharma announces launch of OTREXUP to Dermatologists

Antares Pharma, Inc. today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

10 Mar 2014

NAFC designates Beth Israel Deaconess Medical Center as Center of Excellence

The National Association For Continence has designated Beth Israel Deaconess Medical Center as a Center of Excellence: Continence Care. Anurag K. Das, MD; Roger Lefevre, MD; Janet Li, MD; and Deborah A. Nagle, MD are the principle physicians for this COE.

27 Feb 2014

NIH-funded session in Bethesda to heighten awareness of underactive bladder

Underactive bladder, estimated to affect more than 20 percent of the elderly population, is an unrecognized disease that has a major influence on the health and independence of seniors.

20 Feb 2014

Study: Urgency incontinence is the most troubling urinary symptom in men and women

Urgency incontinence is considered the most troubling urinary symptom in both men and women, according to a recent study published in the leading urology journal, European Urology.

11 Feb 2014

Short-Form OAB questionnaire validated

Researchers from the USA have developed a short form version of the overactive bladder questionnaire, which they say can capture the full spectrum of symptom bother and quality of life impact, while being more convenient than the full version of the test.

10 Feb 2014

Targacept completes patient recruitment in TC-5214 Phase 2b study for treatment of overactive bladder

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced that it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).

10 Feb 2014

Incontinence prophylaxis shows potential in pelvic organ prolapse

Research from Taiwan suggests that combining trocar-guided transvaginal mesh surgery with a midurethral sling in the treatment of women with advanced pelvic organ prolapse could be an effective way to manage associated stress urinary incontinence.

3 Feb 2014

New article outlines different types of incontinence and treatment options

Urinary incontinence affects up to 13% of Australian men and up to 37% of Australian women. There are several types of urinary incontinence, and each has different treatment options.

3 Feb 2014

HoLEP effective for overactive bladder symptoms

Research shows that Holmium laser enucleation of the prostate is effective in improving overactive bladder symptoms and urodynamic parameters in men with benign prostatic hyperplasia.

13 Jan 2014

Mylan launches Tolterodine Tartrate ER Capsules, 2 mg and 4 mg

Mylan Inc. today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Tolterodine Tartrate Extended-release Capsules, 2 mg and 4 mg. Tolterodine Tartrate ER Capsules are the generic version of Pfizer's Detrol LA, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product.

7 Jan 2014

SUI and UUI show complex interrelationship

A study by US researchers has failed to identify any modifiable risk factors for urgency urinary incontinence among women undergoing surgery for stress urinary incontinence.

6 Jan 2014

Young women more likely to have negative urodynamics experience

Research from the USA suggests that while urodynamic testing is well-tolerated by women on the whole, patients who are younger, or have anxiety or depression may have more negative experiences of the procedure than other patients.

24 Dec 2013

Antares Pharma receives Notice of Allowance for new patent application on reconstitutable drugs

Antares Pharma, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent Office for application 13/584,317. This application, along with U.S. Patent 8,251,947 granted in August of 2012, relate to Antares' injector technology for wet-dry injectable drugs such as lyophilized biologicals or peptide drugs that require dry storage to assure stability.

20 Dec 2013

Targacept reports top-line results from TC-5619 Phase 2b trial for negative symptoms in schizophrenia

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today announced top-line results from a Phase 2b clinical trial of TC-5619 as an augmentation therapy for the treatment of negative symptoms of schizophrenia.

17 Dec 2013

Update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation procedures

Uroplasty, Inc. a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today provided an update on reimbursement coverage for Percutaneous Tibial Nerve Stimulation (PTNS) procedures delivered via the Company's Urgent® PC Neuromodulation System for treatment of overactive bladder (OAB) and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

4 Dec 2013

Researchers review effectiveness of Botox injections for overactive bladder symptoms

AN INNOVATIVE treatment helping patients with overactive bladder symptoms lead normal lives again has been licensed for use by the UK’s medicines watchdog following a landmark study in which Sheffield Teaching Hospitals NHS Foundation Trust played a leading role.

6 Nov 2013

Altherx Pharmaceuticals receives U.S. patent for use of solabegron for treatment of overactive bladder

AltheRx Pharmaceuticals, a privately-held clinical development company, today announced the United States Patent and Trademark Office issued a Notice of Allowance for the company's U.S. Patent Application claiming a method of use for solabegron, a beta 3-adrenergic receptor agonist, in combination with all commercially available antimuscarinics at both therapeutic and sub-therapeutic doses for the treatment of overactive bladder (OAB).

18 Oct 2013

FDA approves OTREXUP injection for adults with RA, children with active pJIA

Antares Pharma, Inc. today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration. OTREXUP is the first FDA approved subcutaneous methotrexate for once weekly self-administration with an easy-to-use, single dose, disposable auto injector.

14 Oct 2013

Overactive bladder treatments: an interview with Professor Chris Chapple, Consultant Urological Surgeon at the Royal Hallamshire Hospital and Sheffield Teaching Hospitals NHS Foundation Trust

Overactive bladder symptom complex is a symptom complex, the pivotal symptom of which is urgency, which is a compelling desire to pass urine, which is difficult to defer.

1 Oct 2013